Upper airway manifestations of anti-IgLON5 disease: Otorhinolaryngological point of view.

Estridor Stridor anti-IgLON5 disease bilateral vocal cord palsy disfagia dysphagia parálisis de cuerda vocal sleep disorder sueño tracheostomy traqueotomía

Journal

Acta otorrinolaringologica espanola
ISSN: 2173-5735
Titre abrégé: Acta Otorrinolaringol Esp (Engl Ed)
Pays: Spain
ID NLM: 101770938

Informations de publication

Date de publication:
08 May 2024
Historique:
received: 14 02 2024
accepted: 17 04 2024
medline: 11 5 2024
pubmed: 11 5 2024
entrez: 10 5 2024
Statut: aheadofprint

Résumé

Anti-IgLON5 disease is a recently described neurological disorder with multisystemic features. The disease is characterized by the presence of IgLON5 antibodies in serum and cerebrospinal fluid. Our objective is to describe in detail the otorhinolaryngological manifestations of this disease, which are frequent and may include dysphagia, dysarthria, vocal cord paralysis and laryngospasm. In this study, we present a series of 9 patients with anti-IgLON5 disease and otolaryngological manifestations. Patients were evaluated between July 2012 and March 2022 by video-polysomnography, fiber-optic laryngoscopy, and functional endoscopic evaluation of swallowing. The median age was 71 years, and 5 (56%) were female. Video-polysomnography showed a NREM/REM parasomnia in 6 patients (67%), obstructive sleep apnea in 8 (88%), stridor during sleep in 7 (78%) and central apneas in 1 (11%). Six out of the 9 patients (67%) presented episodes of acute respiratory failure that required mechanical ventilation, 6 had vocal fold palsy with 4 of them requiring tracheostomy (3 had to be performed on an emergency basis). Dysphagia occurred in 8 patients (89%). Prominent upper airway secretion and sialorrhea was also present in 3 cases. The anti-IgLON5 disease exhibits extensive otolaryngological symptoms, mainly affecting the upper airway. These symptoms affect the quality of life and can be life-threatening. Prompt acute management is essential for stridor, dyspnea, and dysphagia. Given the potential severity of the symptoms and rarity of the disease, it is important for otolaryngologists to be familiar with anti-IgLON5 disease. Level 4.

Identifiants

pubmed: 38729239
pii: S2173-5735(24)00051-6
doi: 10.1016/j.otoeng.2024.04.001
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Informations de copyright

Copyright © 2024. Published by Elsevier España, S.L.U.

Auteurs

Daniela Pastene (D)

Otorhinolaryngology Department, Hospital Clínic, Barcelona, Spain.

Eduardo Lehrer (E)

Otorhinolaryngology Department, Hospital Clínic, Barcelona, Spain; Head Neck Cancer Unit, Hospital Clínic, Barcelona, Spain; Department of Surgery and Medical Surgical Specialties, School of Medicine, Universitat de Barcelona, Spain. Electronic address: elehrer@clinic.cat.

Sara Jubes (S)

Otorhinolaryngology Department, Hospital Clínic, Barcelona, Spain.

Joan Santamaria (J)

Emeritus consultant and researcher, Hospital Clínic of Barcelona and Biomedical Research Institute (IDIBAPS) Barcelona, Spain.

Alex Iranzo (A)

Neurology Service, Sleep Disorders Center, Hospital Clínic de Barcelona, Barcelona, Spain, University of Barcelona, IDIBAPS, CIBERNED, Spain.

Carles Gaig (C)

Neurology Service, Sleep Disorders Center, Hospital Clínic de Barcelona, Barcelona, Spain, University of Barcelona, IDIBAPS, CIBERNED, Spain.

Isabel Vilaseca (I)

Otorhinolaryngology Department, Hospital Clínic, Barcelona, Spain; Head Neck Cancer Unit, Hospital Clínic, Barcelona, Spain; Department of Surgery and Medical Surgical Specialties, School of Medicine, Universitat de Barcelona, Spain.

Classifications MeSH